India, Oct. 5 -- Shares of Vaxcyte Inc. (PCVX) are surging 39% on Monday morning after the company reported positive topline results from the pivotal Phase 3 OPUS-1 trial of its 31-valent pneumococcal vaccine candidate VAX-31.
The stock is currently trading at $78.33, up $21.85 or 38.69%, on the Nasdaq. It opened at $87.21 after closing the previous session at $56.48. The stock has traded between $39.87 and $90.75 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....